Silent serologic changes can be demonstrated if viral serologic markers are sought serially. Among them, the Fourty-four patients who underwent allogeneic bone disappearance of serum anti-HBs may be important as marrow transplantation (alloBMT) were studied for it increases the risk of HBV contamination in recipients. hepatitis B virus (HBV)-related complications. The Keywords: allogeneic bone marrow transplantation; mean follow-up period was 15.3 months. Positivity for hepatitis B virus HBV surface antigen (HBsAg) was observed in 10 patients (22.7%) throughout the study. Four of the 10 patients were HBsAg carriers before alloBMT, while the remaining six became HBsAg(+) after alloBMT. During
Recipients are but we were unable to demonstrate the source of HBV.
immunodeficient for months to years post-transplant; nonFive of them had a moderate increase in serum ALT specific components of the immune system recover within activity while the other patient had a normal ALT. Two 2-6 months post-transplant while T cell and B cell funcpatients seroconverted to anti-HBs spontaneously. Two tional reconstitution generally take 1-2 years. Immunopatients died during the follow-up, one due to intrasuppression may cause reactivation of HBV in the host. [9] [10] [11] [12] [13] [14] cranial hemorrhage and the other due to GVHD and HBsAg carrier recipients may develop fulminant hepatitis accompanying pulmonary infection. The rest of the after transplantation during immune reconstitution. 9, 10 study group (34 patients) remained HBsAg(−) throughHowever, some reports suggest that being a carrier of out the study. Two of them had an HBsAg(+) donor, HBsAg is not a contraindication for transplantation. [15] [16] [17] but neither developed HBV infection in their follow-up Some recipients, who have an HBsAg carrier donor, may period. The acquisition rate of HBV infection was relabe infected with the virus after alloBMT. A case illustrating tively low in recipients who were positive for anti-HBs this has been reported 18 in which the patient developed fulcompared to those who were negative for anti-HBs (8 minant hepatitis B infection and died of liver failure after vs 19%). Anti-HBs positivity remained for a longer pertransplantation. On the other hand, alloBMT may be advaniod in recipients who received marrow from anti-HBs tageous for the outcome of HBV infection. If transplanpositive donors compared to those recipients who had tation takes place with a donor who is immune to HBV, anti-HBs negative donors (median 12 vs 3 months). We the recipient may clear the virus (adoptive immune think that HBV is a frequent cause of liver dysfunction response). 15, 19 Our patients were examined to determine the in alloBMT patients where HBV infection is endemic.
frequency of HBV infection and the effects of alloBMT Whether the disease is in the form of reactivation of during the course of HBV infection. Our goal was to HBsAg-positive recipients, or is acquired from unknown sources in recipients who never had contact observe and define events related to HBV in recipients and with the virus, the course of the disease is not fatal.
answer the question of whether or not carrying HBV in recipients and/or donors is a contra-indication to alloBMT.
Materials and methods

Histological techniques
Twenty-two liver specimens were obtained from 19 Patients patients by percutaneous liver biopsy. All liver tissue samples were fixed in 10% buffered formalin and embed-A total of 44 consecutive patients who underwent alloded in paraffin. Sections were routinely stained with hemageneic bone marrow transplantation in the Ibn-i Sina Hospitoxylin-eosin. The periodic-acid Schiff (PAS) stain was tal, Dept of Hematology between 1989 and 1995 were used to evaluate bile duct damage. Masson's trichrome was included in the study. Twenty-two patients had acute nonperformed to show fibroelastic activity. Hepatitis B virus lymphocytic leukemia (ANLL), 16 chronic myeloid leukesurface and core antigens were detected by immunohistomia (CML), three acute lymphocytic leukemia (ALL), one chemical (IHC) examination (Biogenex, Dublin, Eire). IHC severe aplastic anemia (SAA), one myelodysplastic synexamination for HCV and CMV was also carried out on drome-refractory anemia (MDS-RA) and one had adrenoliver specimens. leukodystrophy. Twenty-seven were male and 17 female. The mean age at transplantation was 22 years (range 15-41 years). The mean follow-up after alloBMT was 15.3 Results months (range 12 days to 52 months).
In recipients, the mean pre-transplant frequency of HBsAg positivity and anti-HBs positivity was 9% (4/44) and 31.8% Conditioning regimen and GVHD prophylaxis (14/44), respectively. The rate of HBsAg positivity and anti-HBs positivity in donors was 4.5% (2/44) and 31.8% Patients with leukemia were conditioned with a combi-(14/44), respectively. Four patients were HBsAg-positive nation of busulfan, 4 mg/kg for 4 consecutive days, folbefore alloBMT and six became HBsAg positive after lowed by cyclophosphamide 60 mg/kg/day for 2 days.
alloBMT making a total of 10 (22.7%) HBsAg-positive 1250 cGy total body irradiation was used in 12 patients.
patients. Two main types of hepatitis B virus (HBV)-related Patients with SAA received anti-thymocyte/lymphocyte events were noted in recipients. The first type (type 1) of globulin, 30 mg/kg/day for 3 days and cyclophosphamide event, which occurred in 10 patients, was serum HBsAg 50 mg/kg/day for 4 days. GVHD prophylaxis was with positivity with an accompanying increase in serum ALT cyclosporine and methotrexate.
activity and other changes in HBV-related serologic markers (four patients in group 1, one patient in group 4, two patients in group 5 and three patients in group 6). The Virology second type (type 2) of event occurred in 13 (29.5%) patients and consisted of changes only in HBV-related seroHepatitis B surface antigen (HBsAg), hepatitis B surface logic markers. Type 2 events were all asymptomatic, withantibody (anti-HBs), hepatitis B 'e' antigen (HBeAg), hepaout an increase in serum ALT activity, and featured only titis B 'e' antibody (anti-HBe), hepatitis B core antibodies as changes in serum anti-HBs and anti-HBe positivity. (anti-HBc IgM/G), hepatitis delta antibody (anti-D) of sera
In those 10 patients with serum HBsAg positivity and were all assayed with second generation enzyme-linked an increase in serum ALT activity other causes of necroimmunosorbent assay (ELISA) (Abbott Laboratories, North inflammatory reaction within the liver were sought. SuperChicago, IL, USA). These viral markers were tested in all infection or coinfection were not detected in any of the patients before transplantation and in those who had liver HBsAg(+) patients. Serum anti-HCV, HCV-RNA, CMVdysfunction after transplantation. In 44 patients, HBVIgM, EB-IgM, anti-HIV were all sought and found to be related serologic markers were assayed at intervals of 3 negative in these patients. Liver biopsies and IHC examinmonths during the first 6 months, then at 6-month intervals ation for HBsAg, HBcAg, HCV (all negative) and CMV throughout the study. In some patients the polymerase chain (all negative) were performed in only eight patients and the reaction (PCR) technique was used for the detection of details were given in the following section. The alloBMT HCV-RNA and HBV-DNA.
patients were classified into six groups according to HBVrelated serologic markers of recipients and donors.
Liver function Group 1: HBsAg carrier recipients (n = 4) Aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), lactate Four patients developed a HBV-related type 1 event in this group. Before alloBMT all patients had normal serum ALT dehydrogenase (LDH), alkaline phosphatase (AP) and bilirubin were measured on a 24 factor automated chemical values and serum HBeAg positivity was found in only one patient, while serum anti-HBe positivity was found in the analyser using standard reagents. The normal range is below 40 U/l for AST, ALT and GGT, 160 U/l for AP, 280 remaining three patients (Table 1) . Within the 4 to 5 months following transplantation, HBcIgM appeared in the serum U/l for LDH, 1.4 mg/dl for bilirubin. The tests were carried out at 3-day intervals during the first month after bone marof two patients paralleling the increase in serum ALT activity. When the dose of cyclosporine was reduced 5 row transplantation (BMT), and then every 2 weeks for the next 3 months. Patients were subsequently evaluated every months after alloBMT, an elevation in the serum transaminase activities was detected in all of the patients. The rise 6 months. Recipient serum HBeAg/anti-HBe/anti-HBc- Latest clinical status +45th month/alive +28th month/alive +35th month/alive +6th month/dead CAH = chronic active hepatitis; CLH = chronic lobular hepatitis.
in serum ALT levels was moderate (less than 10 times the dysfunction. The other patient died of diabetic ketoacidosis, deterioration of liver function and GVHD at 6 months upper limit of the normal (ULN) range) in three patients and severe (10 times above the ULN range) in one patient.
following alloBMT. Jaundice occurred in the patient who had severely increased serum ALT activity, while in the remaining three, jaundice never developed. HBV-DNA was positive in this period in Group 2: HBsAg carrier donors (n = 2) three patients and not studied in the other patient. Histological diagnosis of CH was confirmed in all four patients. The
Both patients underwent alloBMT for CML. Neither had any change in HBV serologic markers throughout the postnecro-inflammatory reaction in the liver was severe (grade 7-13) with a moderate fibrosis score (stage 2 in two patients transplant follow-up periods ( Table 2 ). One of the two patients had liver dysfunction starting from the +2nd month and stage 1 in the other two patients) in all patients. IHC staining was carried out in three of the four liver samples.
and lasting up to +12th month after transplantation. However, the cause of the liver damage could not be determined. Cytoplasmic HBsAg positive staining was detected in all three patients (Nos 1, 2 and 3), but HBcAg-positive staining
The patient is still alive with normal liver function in the +34th month after alloBMT, but the other patient died of was detected in only two (Nos 1 and 2).
Two of the four patients had anti-HBs-positive donors. intracranial haemorrhage within 3 months of alloBMT. The disappearance of HBsAg and appearance of anti-HBs was detected 8 months after alloBMT in one. Interferon alpha-2b, 3 MU three times a week was used in this patient, Group 3: Recipients and donors both HBsAg-negative for 2 months (from +5th month to +7th month) for the treatand anti-HBs-positive (n = 5) ment of CH. It was discontinued due to pneumonitis.
In one of the two patients who had had an anti-HBs-HBV related type-1 events did not occur in any patient in this group (Table 3) . Anti-HBs positivity remained in all negative donor, pulmonary tuberculosis developed when the HBsAg titer decreased, and the anti-HBs appeared in patients for a median of 12 months after alloBMT but in the first patient it disappeared from the serum 14 months low titer in his serum. Anti-HBs disappeared after the development of pulmonary tuberculosis. The serum transafter alloBMT. Four (Nos 2, 3, 4 and 5) still had anti-HBs at the time of their last visit. However, anti-HBe positivity aminase activity gradually decreased to normal in three patients. Three of four patients are still alive without liver became negative in three patients (Nos 1, 2 and 3). 
Group 4: HBsAg-negative, anti-HBs-positive recipients, Group 5: HBsAg and anti-HBs negative recipients, HBsAg(−) and anti-HBs(+) donors (n = 7) HBsAg and anti-HBs-negative donors (n = 7)
Only one (No. 2) developed a HBV-related type 1 event in HBV-related type-1 events occurred in two patients (Nos 2 and 4) ( Table 5 ). Serum HBsAg was positive 6 months after the +39th month ( Table 4 ). At that time the patient's serum HBsAg, HBeAg and HbcIgM was positive with a moderate alloBMT in one (No. 2) of the two. Serum HBeAg and HBcIgM positivity accompanied this change with a moderincrease in serum ALT activity and normal bilirubin levels. HBV-related markers were all negative up to the +39th ate increase in serum ALT activity. One year later, the patient cleared the HBsAg and anti-HBs and anti-HBe month. Clinical signs of GVHD with consistent liver changes developed in the +24th month. Liver biopsy developed, with spontaneous resolution of the hepatitis. Notably, the pre-transplant HBcIgG was positive in the revealed biliary stasis and focal necroinflammatory changes, and negative staining for HBsAg and HBcAg.
serum. In the other patient serum HBsAg, HBeAg and HBV-DNA (95 pg/ml) were all demonstrated to be positive Anti-HBs seropositivity disappeared after alloBMT in four patients (Nos 1, 3, 5 and 7) in the 3rd, 3rd, 9th and 12th at 1 month after alloBMT. Pre-transplant serum HBcIgG was not known in this patient, but 20 days after alloBMT it months, respectively. Anti-HBe positivity, which was detected in only one patient, No. 2, before transplantation, was found to be positive. Serum ALT activity was slightly increased at that time but the patient died of septicaemia disappeared in the +24th month after alloBMT with the development of GVHD.
while his liver function tests were impaired. In the 18 was never demonstrated but anti-HBe developed at 6 months. Immunosuppressive therapy ended at 9 months and Among these, three patients developed HBV-related type 1 event (Nos 17, 18 and 19) ( Table 6) .
following 1 month of severe hepatitis, seroconversion to anti-HBs occurred spontaneously with complete resolution of the hepatitis. Patient 17: Serum HBsAg and HBeAg appeared to be positive at 1 month after alloBMT without serum HBcIgM positivity. Serum ALT activity remained within normal Patient 19: Serum HBsAg appeared at 3 months after alloBMT with accompanying HBcIgM and HBeAg positilimits. Liver biopsy at that time revealed minimal hepatitis, steatosis and hemosiderosis. HBsAg and HBcAg were not vity which remained throughout the observation period (20 months). Serum HBV-DNA was undetectable. Serum ALT apparent on IHC examination. When this patient was followed, serum HBcIgM positivity appeared at 6 months paractivity was normal at 3 months but increased moderately at 6 and 9 months after alloBMT. Initial liver biopsy which allel to the moderate increase in serum ALT activity while the dose of cyclosporine was reduced. He remained HbeAgwas performed in the +3rd month was not diagnostic but subsequent liver biopsies, performed in the +6th month and positive and serum ALT activity returned to normal limits at 12 months spontaneously. the +8th month, were consistent with GVHD and CH Table 6 HBV-related serologic events in group 6 (both recipients and donors negative for HBs Ag and anti-HBs) . Cytoplasthe event and serum HBV-DNA was positive during exacerbations of the disease, indicating the possibility of mic HBsAg positivity was detected in the last specimen, but it was not found in the first and second specimens.
Patient Pretransplant Post-transplant period (month)
this type of mutation. After alloBMT, serum HBV-DNA was assayed in three Nuclear HBcAg staining was negative in all specimens. The patient died of GVHD and pulmonary infection 20 months patients and found to be positive in all, indicating active viral replication. These findings are consistent with the after alloBMT.
Two patients were alive with normal serum ALT activity, suggestion of some reports that immunosuppression causes viral replications. [9] [10] [11] [12] [13] [14] but in one of them HBeAg was positive. There were no changes in the HBV-related serologic markers in the Another specific serologic marker of acute disease, antiHBc-IgM, was found to be positive in two patients during remaining patients.
the event. This is not always positive in patients with chronic hepatitis B, and acute exacerbation of the disease though this was the cause in our patients. ImmunohistoDiscussion chemical testing is crucial in evaluation of necro-inflammation found in chronic hepatitis B as it may be due to The liver is one of the organs most effected by alloBMT. 1 The effects of alloBMT on the liver vary greatly. Besides
(1) conversion of chronic HBV infection from the replicative to the nonreplicative phase; (2) spontaneous reacti-GVHD of the liver and veno-occlusive disease, viral infections can cause hepatitis of variable severity after BMT.
vation of HBV replication during the nonreplicative phase; (3) superinfection of chronic hepatitis B by other viruses; Impairment of immune response in BMT patients can effect the clinical and serologic outcome of HBV infection as the (4) reactivation of HBV replication following withdrawal of immunosuppressive therapy. The expected expression severity of the disease depends mainly on the immune system's ability to attack infected hepatocytes. It has been sugpattern of hepatitis markers in this latter group is positive nuclear HBcAg and cytoplasmic HBsAg in liver tissue.
21
gested that HBV-related liver disease after BMT may be more severe in this setting and, indeed, fulminant liver We have seen a similar staining pattern in all cases, except for negative nuclear HBcAg staining in only one case, refailure was seen more frequently in patients with HBsAgpositive donors when compared with their negative inforcing the diagnosis of reactivation of HBV replication rather than reinfection with HBV. 15, 16 Anti-HBs positivity counterparts.
In Europe, the median prevalence of HBsAg-positive was observed 8 months after alloBMT in one patient who received marrow from an anti-HBs-positive donor. At least BMT candidates has been reported as 3.5%, with a range of 0 to 15%. 4 In Turkey, nearly 33% of the population 1 year after transplantation was required for the antibody response to recall antigens. [6] [7] [8] It is logical to explain the acquire HBV and the median prevalence of HBsAg positivity in the community is 5%. The rate of serum HBsAg appearance of anti-HBs as an adoptive immune response. 15, 19 The use of interferon might also have played positivity was 9% (four BMT candidates) and 4.5% (two recipients) before transplantation and six (13.7%) patients a role in the clearance of the HBsAg from the serum of the patient, but the total dose and duration of interferon treatacquired the disease after alloBMT. Therefore, the rate of HBV infection (22.7%) was higher than expected, as six ment for this patient was not adequate as it was discontinued prematurely due to a complication. In addition, intermore patients acquired the disease during the study, and the source is unknown. The high incidence of HBV infection is feron was not used in all the patients in our study because an increased risk of graft rejection with interferon adminisprobably related both to immunosuppression and frequent transfusions of blood and blood products which were tration has been reported. 22 Fulminant hepatitis did not develop in any of the four patients. Some studies have coninadequately screened.
Four patients (group 1) were HBsAg carriers at the time tradicted this finding. 9, 10 None of the four died from hepatic failure due to HBV in the follow-up period of 6 to 45 of transplantation, with normal serum ALT activity, suggesting immune tolerance. Only one patient was serum months. Three of these patients are still alive with normal serum ALT activity. Our data is comparable with the HBeAg-positive, indicating active viral replication. Within the first months after alloBMT, serum ALT activity did not suggestion that HBV carriage is not an absolute contraindication for BMT. [15] [16] [17] change as a result of profound immunosuppression, but silent viral replication was occurring. Later, 4-5 months It has been reported that hepatitis B may be acquired from HBsAg-positive donors. 18 We have only two donors after alloBMT, when immunosuppressive drugs were decreased, immune activity was restored as was evident in with HBsAg positivity and their recipients (group 2) did not acquire the disease throughout the study period. This the increase in serum ALT activity which was moderate in three patients and severe in one patient. This information may be due to the presence of protective anti-HBs, and to the small number of our recipients. is consistent with the findings that liver damage caused by HBV infection occurs via the immune system, rather than
The recipients in groups 3 and 4 both had serum antiHBs positivity before alloBMT, but the donor serologic as a direct effect of the virus. 5 We did not look for the presence of serum HBV-DNA before alloBMT, but this is markers (anti-HBs(+) in group 3, and the anti-HBs(−) in group 4) were different. This difference appeared to be important in anti-HBe-positive patients who may harbour an HBV strain with a mutation in the precore region of the important after transplantation as serum anti-HBs positivity disappeared between 3 to 12 months in four patients in genome that blocks synthesis of HBeAg, but who still have replicating HBV. 20 On the other hand, serum HBeAg/antigroup 4, while only one patient was anti-HBs negative after 14 months in group 3. These patients are at risk of acquiring HBe status was identical in all patients before and during a fresh hepatitis B infection especially in endemic areas, negative in group 6 and we did not expect any HBV-related and vaccination against HBV should be considered for event in these patients. To our surprise, three hepatitis B them.
cases were identified during follow-up. The source of infec-HBV infection developed in only one of the 12 patients tion was unknown in all cases but multiple blood trans-(8%) who had anti-HBs antibody before transplantation fusions might be the source of it as only HBsAg positivity (groups 3 and 4), but it developed in five of the 26 patients was sought in blood donors in some centers. Although all (19%) who did not have anti-HBs before transplantation of them were fresh hepatitis cases, serum ALT activities (groups 5 and 6). The source of HBV infection could not be were normal or slightly increased when HBsAg was found determined in the patient who was in group 4, but negative to be positive due to the immunosuppressive therapy, but staining for HBV-related antigens in the liver tissue sugas soon as the dose of therapy was decreased or following gests that it was not a reactivation but a freshly acquired withdrawal of therapy, serum ALT activity increased and infection. Similarly HBV may be acquired from improperly one patient even seroconverted to anti-HBs at that time. checked transfusions in group 5 as they have a history of The outcome of this kind of immune attack is unpredictmultiple transfusions, but the presence of anti-HBcIgG able. Few fatal reactivations have been reported even in before transplantation raised the possibility of reactivation patients treated with single immunosuppressive agents.
26
of the disease under immunosuppression. Unfortunately On the other hand some studies have suggested that IHC was not performed in these patients for this discrimiantiviral effects of interferon may be enhanced by a short nation. One patient in group 5 spontaneously seroconverted priming course of steroids. 27 to anti-HBs after 1 year. It would be reasonable to assume During the course of chronic hepatitis B infection abunthat the immunity against HBV from the donor side may dant HBcAg with little HBsAg was found within the liver act as a component of the recipient's immune system; it tissue in immunosuppressed patients, which was demonthen intensifies after 1 year and provides immunity against strated in one of the three patients. 21 On the other hand, HBV. These findings suggest that anti-HBs positivity in the the chance of detecting viral particles in liver tissue is low pretransplant period may be protective for HBV infection in acute hepatitis especially in the early incubation period, after transplantation. This is a controversial issue in the which was the case in our two patients in group 6. The late literature. One study reports that pretransplant anti-HBs appearance of HBsAg staining in one patient in group 6 positivity may be protective for recipients who receive marcan be interpreted as a sign of chronicity, and the finding row from HBsAg-positive donors. 23 Other studies suggest of persistent serum HBeAg positivity during the follow-up that HBsAg reappeared when anti-HBs titers fell with period supports this statement. All three patients in this continuing immunosuppression. 14, 15 group survived the hepatitis period without clinical sideIt was shown that donor B lymphocytes could retain their effects and two of them are still alive; one patient died of antibody production ability in the recipient's body for GVHD and accompanying pulmonary infection. nearly 50 days. The demonstration of anti-HBs positivity
In conclusion, we suggest that HBV infection is frequent in two of the seven anti-HBs negative patients (group 5) in alloBMT patients, especially where HBV infection is who received marrow from anti-HBs(+) donors within 1 to endemic. It may cause morbidity, but mortality related to 3 months after alloBMT can be explained in this way. Two HBV infection in alloBMT patients is unlikely. While additional patients developed anti-HBs positivity 12 and 16 investigating the cause of liver dysfunction in alloBMT months after transplantation. The appearance of anti-HBs patients, a detailed search for the presence of HBV should in all patients was not temporary and can be detected be carried out with modern techniques as the clinical and throughout the study, indicating that the donor's immune laboratory presentation may be unusual. Consequently, sersystem became a component of the recipient's immune sysial serologic, virologic and pathologic investigations are tem. None of them received IVIG therapy during the folmandatory. The presence of serum HBsAg positivity is not low-up which could be the source of serum anti-HBs posia contraindication for alloBMT patients. Although the distivity. In the remaining two patients the development of ease exacerbates during withdrawal of immunosuppressive hepatitis B again displayed the importance of the presence therapy the outcome is benign. If possible, the selection of of anti-HBs as a protective antibody. Pretransplant immunianti-HBs positive donors is worthwhile especially in areas zation of the donor may facilitate the transfer of functioning where HBV infection is highly endemic as unexpected B cells and helper T cells which are required for antibody production by B cells. [6] [7] [8] However, even if T cell-depleted hepatitis B cases can be seen. Disappearance of serum antibone marrow is given to recipients, the functioning humoral HBs positivity can be observed in recipients who have immune system can be transferred. 24 Activated natural serum anti-HBs negative donors and the risk of HBV infeckiller cells may play a significant role in stimulating antition is higher in these patients. body production by B cells. 24 When either the donor or the recipient is exclusively immunized with HBV vaccine, then the rise in the antibody of the recipient is of low titer and shorter duration than that observed when both donor and recipient are immunized. 8, 24 The presence of retained antiantitumor for myeloproliferative and lymphoproliferative dis-
